BIO — Biotest AG Income Statement
0.000.00%
- €1.68bn
- €2.23bn
- €726.20m
- 40
- 14
- 40
- 19
Annual income statement for Biotest AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 484 | 516 | 516 | 685 | 726 |
Cost of Revenue | |||||
Gross Profit | 130 | 80.7 | 125 | 280 | 224 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 486 | 563 | 533 | 541 | 632 |
Operating Profit | -1.3 | -47.1 | -16.6 | 144 | 94.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -30 | -62.6 | -30.8 | 106 | 46.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -31.4 | -63.3 | -31.6 | 127 | 26.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -31.4 | -63.3 | -31.6 | 127 | 26.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -32.2 | -65 | -32.5 | 127 | 26.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.83 | -1.69 | 0.449 | 1.53 | 0.268 |
Dividends per Share |